Key Mesenchymal Precursor Cell Patents Granted in United States and China

Wed Feb 6, 2013 7:41pm EST

* Reuters is not responsible for the content in this press release.

MELBOURNE, Australia, Feb. 6, 2013 (GLOBE NEWSWIRE) -- Regenerative medicine company Mesoblast
Limited (ASX:MSB) (USOTC:MBLTY) today announced that it has been granted three key new patents by
the United States Patent and Trade Mark Office (USPTO) and the State Intellectual Property Office
of the People's Republic of China. These patents deliver major commercial advantages and offer
long term protection in these territories for the company's products based on its proprietary
Mesenchymal Precursor Cell (MPC) adult stem cell technology platform. 
In the United States, USPTO patent 8,367,405 confers Mesoblast with exclusive rights through to
March 2029 to compositions-of-matter covering its current products. This patent extends by more
than seven years Mesoblast's exclusive commercial rights in the United States, the world's largest
healthcare market, to MPC compositions-of-matter beyond those rights already conferred by USPTO
patents 7,122,178 and 8,158,118 whose expiry had previously been extended to November 2021.

In China, patents CN200580040212.1 and CN200580039970.1 provide Mesoblast with exclusive MPC
product commercial rights and protection through to 2025. These patents provide Mesoblast with
long-term composition-of-matter protection for the company's MPC products derived from an
unlimited range of tissue sources, such as bone marrow, adipose tissue, placenta, umbilical cord,
and dental pulp. These Chinese patents underpin Mesoblast's corporate strategy to target the
world's largest emerging market for regenerative medicines, and to protect its manufacturing
processes and know-how.

Mesoblast Limited

Mesoblast Limited is a world leader in the development of biologic products for the broad field of
regenerative medicine. Mesoblast's patented Mesenchymal Precursor Cell (MPC) technology is being
developed for a broad range of major clinical diseases, including inflammatory and immunologic
conditions, diabetes and its complications, orthopedic spine conditions, and cardiovascular

CONTACT: Julie Meldrum
         Global Head of Corporate Communications
         T: +61 3 9639 6036

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.